Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on November 1, 2022. The filing reports the appointment of a new member to the Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer (Director): $45,000
- Annual Cash Retainer (Committee): $5,000
- Initial Stock Option Grant (Black-Scholes Value): $350,000
Material Changes
The primary material change reported is the appointment of Lisa von Moltke, M.D. to the Board of Directors, effective November 1, 2022. She was also appointed to the Nominating and Corporate Governance Committee. Her term expires at the 2023 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Dr. von Moltke brings significant experience, having served as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. since April 2020, and previously held senior roles at Alkermes, Inc. The stock option grant is scheduled to vest over three years in twelve equal quarterly installments.
Important Facts for Investors to Verify
- Confirm the correct registrant name is Cara Therapeutics, Inc., as the input metadata referenced "Tvardi Therapeutics, Inc."
- Verify the vesting schedule and exercise terms of the $350,000 stock option grant in the full compensation agreement.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Note that this filing does not provide updated financial statements or liquidity positions.